Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma

American Journal of Clinical Pathology

Volumn 132, Issue 5, 2009, Pages 728-732

  Gupta, Ritu ^a   Bhaskar, Archana ^a   Kumar, Lalit ^a   Sharma, Atul ^a   Jain, Paresh ^a,b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b BD Biosciences ^*  (India)

Author keywords

Immunophenotype; Minimal residual disease; Multi parametric flow cytometry; Multiple myeloma

Indexed keywords

CD19 ANTIBODY; CD20 ANTIBODY; CD45 ANTIGEN; CD52 ANTIGEN; CD56 ANTIGEN; STEM CELL FACTOR RECEPTOR; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CLINICAL EVALUATION; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIGENS, CD; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; TUMOR MARKERS, BIOLOGICAL;

EID: 70449717409     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP1GYI7EHQYUYK     Document Type: Article

References (19)

1. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883. (Pubitemid 36532313)
2. Corso A, Varettoni M. The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation? Curr Stem Cell Res Ther. 2007;2:1-11. (Pubitemid 46723142)
3. Srikanth M, Davies FE, Morgan GJ. An update on drug combinations for treatment of myeloma. Expert Opin Investig Drugs. 2008;17:1-12. (Pubitemid 351578206)
4. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431-438.
5. Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-488. (Pubitemid 38392955)
6. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55. (Pubitemid 27179563)
7. Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100:3095-3100.
8. Kobayashi S, Hyo R, Amitani Y, et al. Four-color flow cytometric analysis of myeloma plasma cells. Am J Clin Pathol. 2006;126:908-915. (Pubitemid 44901844)
9. Moreau P, Voillat L, Benboukher L, et al. Rituximab in CD20 positive multiple myeloma [letter]. Leukemia. 2007;21:835-836. (Pubitemid 46444580)
10. Carlo-Stella C, Guidetti A, Di Nicola M, et al. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vitro in NOD/SCID mice. Exp Hematol. 2006;34:721-727. (Pubitemid 44240317)
11. Pandiella A, Carvajal-Vergara X, Tabera S, et al. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol. 2003;123:858-868. (Pubitemid 37533298)
12. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biological considerations and therapeutic applications. J Immunother. 2002;25:72-81.
13. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473. (Pubitemid 44264086)
14. de Tute RM, Jack AS, Child JA, et al. A single-tube six-color flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia. 2007;21:2043-2046.
15. Morice WG, Hanson CA, Kumar S, et al. Novel multiparameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia. 2007;21:2046-2049.
16. Sarasquete ME, García-Sanz R, González D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90:1365-1372. (Pubitemid 41503652)
17. Bakkus MH, Bouko Y, Samson D, et al. Post-transplantation tumor load in bone marrow, as assessed by quantitative ASOPCR, is a prognostic parameter in multiple myeloma. Br J Haematol. 2004;126:665-674. (Pubitemid 39221301)
18. San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99:1853-1856. (Pubitemid 34533063)
19. Cao W, Goolsby CL, Nelson BP, et al. Instability of immunophenotype in plasma cell myeloma. Am J Clin Pathol. 2008;129:926-933.